Our Unique Drug Discovery Platform. High-throughput discovery platform that identifies TCR in 6 weeks as compared to years of industry average.

CHECK-T Armored T-Cell Platform to Combat Immunosuppression. Next generation Cell drug armored with checkpoint blockade to improve solid tumor outcomes.

TURBO-T Platform for Tumor Cell Heterogeneity. New generation TCRT armored with tumor microenvironment reconditioning agent to enable the endogenous immunity against tumor heterogeneity.

Industrialized production of GMP-grade vectors and engineered immune cells are the basis for clinical development of immune cell therapy. The Chongqing site was launched in 2017, and the facilities in LA and Guangzhou were launched in 2019 and 2020, respectively.

Optimize cord blood NK cell isolation, culturing, transgene, proliferation and differentiation technologies to ensure efficient transfection and amplification of NK cells. The unique drug design gives full play to the advantages of NK cells as general drugs and spot drugs.

TCRCure’s deep sequencing and big data analysis platform supports immune monitoring services. This service can provide valuable data to pharmaceutical companies running clinical trials on immunotherapy drugs. TCRCure has already provided this service to many well-known pharmaceutical companies including BMS.